Myeloma Patients Europe (MPE) is proud to present its Year in Review 2024, highlighting achievements and milestones that reflect our commitment to improving outcomes and quality of life for myeloma and AL amyloidosis patients. This…

Last week Myeloma Patients Europe (MPE) provided feedback, as part of a public consultation, on the new European Medicines Agency (EMA) policy on the handling of competing interests of scientific committees’ members and experts. The…